Future research should aim to evaluate the predictive value of these biomarkers in monitoring treatment response and tracking disease progression.Understanding the correlation between changes in GDF15, TGF-β1, and GDF11 levels and therapeutic outcomes may contribute to the development of individualized treatment strategies for depression. This evidence concerns the gene GDF11 and depressive symptom measurement.